Loading...
Loading...
Credit Suisse raises its price target to $49 (from $44) on Outperform-rated St. Jude Medical
STJ, following doctor call on Riata.
Credit Suisse says, "Yesterday we spoke with doctor who presented on Riata/Riata ST related deaths at ACC. ...This presenter also noted he believes Riata ST likely has a true overall failure rate of ~0.5%/year, which he deemed clinically acceptable. We expect Durata's design improvements to drive an even lower overall failure rate than Riata ST's which should ameliorate Durata-related headline risk as the year progresses."
STJ closed at $43.80 a share on Monday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in